A group of patients (n = 29) with moderate-to-severe ARDS and hyperinflammation were given high dose Anakinra (5 mg/kg twice a day) and compared to low dose and non-Anakinra-treated group controls. The experimental group experienced reductions in inflammatory serum C-reactive protein and respiratory function improvement (72%), and five were on mechanical ventilation. Outcomes were significantly improved in the experimental group (p = 0.009). This highlights the potential benefits of Anakinra treatment but will require a randomized control trial for complete verification.